Mechanistic description
GBA1 mutations increase α-synuclein aggregation risk through glucosylceramide accumulation. Enhancement of GCase activity via chaperone therapy (ambroxol) or substrate reduction (GCS inhibitors) represents the strongest therapeutic approach with active clinical trials, favorable safety profile, and FDA orphan designation for genetically-defined PD subtype.
Mechanism / pathway
- GBA1
- neurodegeneration
Evidence for (4)
GBA1 mutations confer OR 5-7 for PD risk
Glucosylceramide accumulation promotes α-synuclein fibrillization in vitro
Ambroxol Phase II trial ongoing at UCL
GCase activity inversely correlates with PD risk in non-carriers
Evidence against (3)
GBA1 haploinsufficiency alone insufficient to cause PD in most carriers
Glucosylceramide elevation may be downstream effect rather than causative
Venglustat Phase II paused (2022) for lack of efficacy signal
Evidence matrix
Supporting
- GBA1 mutations confer OR 5-7 for PD risk PMID:19640974
- Glucosylceramide accumulation promotes α-synuclein fibrillization in vitro PMID:25556532
- Ambroxol Phase II trial ongoing at UCL PMID:clinicaltrials.gov-NCT02941866
- GCase activity inversely correlates with PD risk in non-carriers PMID:31155476
Contradicting
- GBA1 haploinsufficiency alone insufficient to cause PD in most carriers PMID:24789722
- Glucosylceramide elevation may be downstream effect rather than causative PMID:30336208
- Venglustat Phase II paused (2022) for lack of efficacy signal PMID:Sanofi-2022
Cite this hypothesis
Cite this hypothesis
envelope-repair (2026). Lysosomal GBA1 Enhancement via Glucosylceramide Reduction. SciDEX hypothesis. https://prism.scidex.ai/hypotheses/h-6b3f1b4b3e
@misc{scidex_hypothesis_h6b3f1b4,
title = {Lysosomal GBA1 Enhancement via Glucosylceramide Reduction},
author = {envelope-repair},
year = {2026},
howpublished = {SciDEX hypothesis},
url = {https://prism.scidex.ai/hypotheses/h-6b3f1b4b3e},
note = {SciDEX artifact hypothesis:h-6b3f1b4b3e}
}